5-Fluorouracil Therapeutic Cheat Sheet
120201202012020
Actinic keratoses represent the most common dermatologic diagnosis in patients older than 45 years old in the United States and account for 5.2 million visits annually.1 Cutaneous field cancerization represents areas with a high burden of both clinical and subclinical actinic damage. Cryotherapy can often be combined with topical chemotherapy for a synergistic approach. We continue our series, The …
Actinic keratoses represent the most common dermatologic diagnosis in patients older than 45 years old in the United States and account for 5.2 million visits annually.1 Cutaneous field cancerization represents areas with a high burden of both clinical and subclinical actinic damage. Cryotherapy can often be combined with topical chemotherapy for a synergistic approach. We continue our series, The … 
Depending on your comfort level with treating scars, you may feel hesitation when taking on treatment for patients with keloids – especially those with skin of color. We all know keloids are more common in skin of color and we have most likely all treated these patients. But how can we improve patient outcomes and limit side effects?
During the 2020 Skin of Color Update, Drs. Maritza Pere … 
Gin nose. Gin blossom. Rum nose. Rum blossom. Brandy nose. Copper nose. Hammer nose. Potato nose. These are some of the disparaging terms that were once used to describe people suffering from rhinophyma. As can be seen, many imply the use of alcohol by the afflicted, which is sadly yet another example of the victim-shaming we so often observe when someone’s appearance or choices make others unco … 
A Recap of the JDD October Podcast
Seborrheic keratoses (SKs), though harmless, are one of the most common patient concerns. Their aesthetic impact makes them one of the most common dermatologic complaints, however treatment options are limited. In this special of the JDD podcast series, Dr. Adam Friedman discusses his group’s article “Managing Seborrheic Keratosis: Evolving Strategies an … 